2024-516549-37-00招募中2 期
A randomized double-blind placebo-controlled multicentre study to assess safety, tolerability, pharmacokinetics and efficacy of Radotinib in Parkinson’s disease.
Il-Yang Pharm Co. Ltd.7 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2024年8月20日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 7
- 主要终点
- Evaluation of safety parameters (AE, vital signs, 12-lead ECG, laboratory parameters, physical exams).
研究概览
简要总结
To evaluate the safety and tolerability of Radotinib (50, 100, 150 and 200 mg), administered during 6 months, compared to placebo, in Parkinson's disease subjects.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Male and Female from 40 to 80 years old
- •Blood Pressure (BP) and Heart Rate (HR) considered NCS by Investigator
- •Electrocardiogram (ECG) recording on a 12-lead ECG considered NCS by Investigator
- •Laboratory parameters within the normal range of the laboratory. Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator
- •Diagnosed with "Clinically Probable Parkinson's disease" according to the MDS clinical diagnostic criteria, with documented onset of symptoms per treating physician's records within three years of the Screening visit
- •Positive DAT-scan (e.g. a striatal dopamine transporter deficit on dopamine transporter imaging by DaT-SPECT, characterized by crescent-shaped areas of asymmetrical aspect, or of symmetrical aspect but of uneven intensity, between the right and the left brain hemisphere) confirmed by local reading
- •Hoehn & Yahr stage ≤ 2.5
- •Without previous symptomatic treatment for PD disease and with current clinical state not requiring started dopaminergic therapy within 6 months from Baseline
- •Absence of another cause than Parkinson disease of the parkinsonian syndrome and other neurovascular comorbidities, confirmed by MRI
- •Female subjects must be not of childbearing potential, e.g., documented evidence that they are surgically sterile (e.g., hysterectomy, partial hysterectomy, bilateral oophorectomy, bilateral tubal ligation), or postmenopausal (at least 12 months since last menses) or using highly effective method of birth control defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intra uterine devices (IUDs), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, condom, until at least one month after the last drug intake associated to a negative pregnancy test at screening.
- •Covered by Health Insurance System
- •Able to understand and to sign the informed consent prior to screening
排除标准
- •Atypical Parkinsonism or drug-induced Parkinsonism
- •Participation in other investigational drug trials within 30 days prior to Screening
- •Any concomitant medication or medication excluded that could put subject at risk, or interfere with study evaluations
- •Subjects currently receiving treatment with a strong CYP3A4 inhibitors or strong CYP3A4 inducers or therapeutic Cumarin derivatives and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs
- •Subjects who are currently receiving treatment with a medication that has the potential to extend QT intervals and can neither stop the administration of the drugs before the start of the IP administration nor switch to other drugs (list of medications that have the potential to prolong QT interval is provided in the Appendix II). If subjects need to start such drug treatments during the study, this will be discussed with the sponsor, IL-YANG PHARM. Co., Ltd.
- •Subjects who are currently receiving treatment with P-gp inducers and that can neither stop the administration of these drugs before the start of the IP administration nor switch to other drugs
- •Gastrointestinal disorder or gastrointestinal disease that may result in a significant change in the absorption of the investigational product
- •Medical history of acute or chronic pancreatitis within the past one year
- •Acute or chronic liver, pancreas, or severe kidney disease that are not associated with the disease
- •Subjects known seropositive to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, or cirrhosis. Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B (HBV DNA < 500 IU/mL or site specific local lab normal range lower limit assessed by investigator), and cured hepatitis C subjects can be enrolled
- •Men subjects who are unwilling to use and appropriate method of contraception during the study
- •Current, or within 60 days of screening, use of any prescription, investigational, or over the counter medication for the symptomatic treatment of PD or to slow the progression of PD
- •Subjects who have hypersensitivity to active ingredient or any of the excipients of this investigational product
- •Any medical condition that might interfere with the protocol except those defined in Section 5.3 of the study protocol
- •Subject unable to attend scheduled visits or to comply to the protocol
- •Subject under legal guardianship or judicial protection
- •Subject in the exclusion period of another protocol
- •No possibility of contact in case of emergency.
- •Prior use of dopaminergic therapy (e.g., levodopa, dopamine agonist, amantadine, rasagiline) for 30 or more days any time in the past.
- •Cognitive impairment (Mini Mental State Examination ≤ 24)
- •Active psychiatric disorder (mood disorders, hallucinations or delirium with strong functional impact and not controlled by medication or which happened during the last 3 months before inclusion)
- •Severe or uncontrolled chronic disease
- •Significant medical history of congenital or acquired bleeding disorders
- •Treatment by Deep Brain Stimulation or continuous infusion of apomorphin/dopa gel
- •Any below impaired cardiac function: - LVEF <45% or < lower bound of normal limit of study site (whichever higher), confirmed by echocardiogram (if the subject has already carried out this examination during the last month before inclusion, he/she will be exempted from retaking this examination, but he/she will have to present the echocardiogram as well as the cardiologist's report. If not, this exam should be performed during the screening period) - Subjects who cannot have QT intervals measured according to ECG - Complete left bundle branch block - Subjects with cardiac pacemakers - Subjects with congenital long QT syndrome or the family history of known long QT syndrome - History of, or presence of symptomatic ventricular or atrial Tachyarrhythmias - Clinically significant resting bradycardia (< 50 bpm) - Mean QTcF >450msec following three consecutive ECG tests at baseline: Screening test will be performed again for QTcF after the adjustment of electrolyte if QTcF >450msec and the electrolyte is not within the normal range - Medical history of clinically confirmed myocardial infarction - Medical history of unstable angina (within last 12 months) - Other clinically significant cardiac disease (e.g. congestive heart failure, or uncontrolled hypertension)
结局指标
主要结局
Evaluation of safety parameters (AE, vital signs, 12-lead ECG, laboratory parameters, physical exams).
Evaluation of safety parameters (AE, vital signs, 12-lead ECG, laboratory parameters, physical exams).
次要结局
- Pharmacokinetics assessments of Radotinib HCl: Cmax, Tmax, Ctrough, AUCt, AUCinf, AUC0-12h, Kel, t1/2, %AUCextra, Vd/F, CL/F, R.
- Change from Baseline in the sum of MDS-UPDRS Parts I, II and III after 24 weeks of treatment.
- Time from baseline to initiation of dopamine-replacement medication.
- Change in health related quality of life as measured by a quality of life questionnaire (PDQ-39).
- Subject's clinical global impression of change.
研究者
Martin Giblin
Scientific
Il-Yang Pharm Co. Ltd.
研究点 (7)
Loading locations...
相似试验
招募中
3 期
Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients2023-503755-10-00Association International Extranodal Lymphoma Study Group90
已完成
2 期
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical
Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred
With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or
Fusions2023-510306-40-00Janssen Cilag International6
已完成
2 期
Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM).2024-516808-42-00Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL62
招募中
2 期
Phase II study of Roginolisib in UM patients2024-514333-37-00iOnctura SA43
招募中
2 期
Multicenter, open-label, phase II study in patients with immunoglobulin M monoclonal gammopathy of unknown significance and Myelin Associated Glycoprotein antibodies related polyneuropathy and Zanubrutinib Treatment2023-505933-29-00University Medical Center Utrecht42